Search Results - "van den Reek, Juul M. P. A"

Clinical, laboratory, and genetic markers for the development or presence of psoriatic arthritis in psoriasis patients: a systematic review by Mulder, Michelle L. M, van Hal, Tamara W, Wenink, Mark H, Koenen, Hans J. P. M, van den Hoogen, Frank H. J, de Jong, Elke M. G. J, van den Reek, Juul M. P. A, Vriezekolk, Johanna E

“…Abstract Twenty to thirty percent of psoriasis (Pso) patients will develop psoriatic arthritis (PsA). Detection of Pso patients that are (at risk for)…”
Get full text

Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study by van der Schoot, Lara S, van den Reek, Juul M. P. A, Grine, Lynda, Schots, Lisa, Kievit, Wietske, Lambert, Jo L. W, de Jong, Elke M. G. J

“…Abstract Background Psoriasis is a chronic immune-mediated inflammatory skin disease for which biologics are effective treatments. Dose reduction (DR) of the…”
Get full text

Blood-Based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients by Mulder, Michelle L M, He, Xuehui, van den Reek, Juul M P A, Urbano, Paulo C M, Kaffa, Charlotte, Wang, Xinhui, van Cranenbroek, Bram, van Rijssen, Esther, van den Hoogen, Frank H J, Joosten, Irma, Alkema, Wynand, de Jong, Elke M G J, Smeets, Ruben L, Wenink, Mark H, Koenen, Hans J P M

“…Psoriasis (Pso) is a chronic inflammatory skin disease, and up to 30% of Pso patients develop psoriatic arthritis (PsA), which can lead to irreversible joint…”
Get full text

Association of HLA-C06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis by van Vugt, Lieke J, van den Reek, Juul M P A, Hannink, Gerjon, Coenen, Marieke J H, de Jong, Elke M G J

“…Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small…”
Get more information

Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands by Soegiharto, Reineke, Westmeijer, Mike, Boekema-Bakker, Nicole, Groenewegen, Irene A M, Knulst, André C, van den Reek, Juul M P A, Röckmann, Heike

“…We present a large population-based study on the prevalence and healthcare usage of patients with chronic urticaria (CU) in primary care. The observed annual…”
Get full text

Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment by Menting, Stef P, Coussens, Emma, Pouw, Mieke F, van den Reek, Juul M P A, Temmerman, Linda, Boonen, Hugo, de Jong, Elke M G J, Spuls, Phyllis I, Lambert, Jo

“…Adalimumab has proven to be effective in suppressing psoriasis disease activity and is administered in a standard dose. To establish a therapeutic range for…”
Get more information

Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry by Spekhorst, Lotte S, de Graaf, Marlies, Zuithoff, Nicolaas P A, van den Reek, Juul M P A, Kamsteeg, Marijke, Boesjes, Celeste M, Romeijn, Geertruida L E, Loman, Laura, Haeck, Inge, Oosting, Albert J, de Boer-Brand, Astrid, Touwslager, Wouter R H, Flinterman, Annebeth, van Lynden-van Nes, Anneke M T, Gostynski, Antoni H, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise

“…Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with…”
Get more information

Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial by Atalay, Selma, van den Reek, Juul M P A, den Broeder, Alfons A, van Vugt, Lieke J, Otero, Marisol E, Njoo, Marcellus D, Mommers, Johannes M, Ossenkoppele, Paul M, Koetsier, Marjolein I, Berends, Maartje A, van de Kerkhof, Peter C M, Groenewoud, Hans M M, Kievit, Wietske, de Jong, Elke M G J

“…Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible. To investigate whether dose…”
Get more information

Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up by Menting, Stef P, van Lümig, Paula P M, de Vries, Anna-Christa Q, van den Reek, Juul M P A, van der Kleij, Desiree, de Jong, Elke M G J, Spuls, Phyllis I, Lecluse, Lidian L A

“…In a previously reported cohort of 29 patients with plaque-type psoriasis followed up for 24 weeks, clinically relevant antidrug antibody (ADA) to adalimumab…”
Get more information

Effectiveness and Safety of Systemic Therapy for Psoriasis in Older Adults: A Systematic Review by van Winden, Marieke E C, van der Schoot, Lara S, van de L'Isle Arias, Mariluz, van Vugt, Lieke J, van den Reek, Juul M P A, van de Kerkhof, Peter C M, de Jong, Elke M G J, Lubeek, Satish F K

“…Treating older adults with psoriasis can be challenging owing to comorbidities, concomitant medication use, and consequent safety risks. Although many studies…”
Get more information

Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks by Ter Haar, Elke L. M., Van den Reek, Juul M. P. A., Gaarn Du Jardin, Kristian, Barbero-Castillo, Almudena, De Jong, Elke M. G. J., Lubeek, Satish F. K.

“…The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among…”
Get full text

Trends in three major histological subtypes of cutaneous melanoma in the Netherlands between 1989 and 2016 by Niekerk, Catharina C., Otten, J. Hans D. M., Rossum, Michelle M., Reek, Juul M. P. A., Brummelkamp, Erik, Mol, Martijn, Groenewoud, J. Hans M. M., Verbeek, André L. M.

“…Background Time trend analysis of cutaneous melanoma (CM) mortality in fair skin populations shows both a gradual decrease and/or an increase. To explain these…”
Get full text

Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID) by Kwee, Kevin V., Murk, Jean-Luc, Yin, Qiqi, Visch, M. Birgitte, Davidson, Linda, de Jong, Elke M. G. J., van den Reek, Juul M. P. A., Tjioe, Milan

“…The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is…”
Get full text

Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients by Dekkers, Coco, Alizadeh Aghdam, Mehran, Graaf, Marlies, Knulst, André C., Meijer, Yolanda, Reek, Juul M. P.A., Stadermann, Marike B., Röckmann, Heike, Sampson, Hugh

“…Background Evidence on safety and effectiveness of omalizumab for treatment of chronic urticaria in pediatric patients is scarce and limited to case reports…”
Get full text

Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial by Atalay, Selma, van den Reek, Juul M P A, van Vugt, Lieke J, Otero, Marisol E, van de Kerkhof, Peter C M, den Broeder, Alfons A, Kievit, Wietske, de Jong, Elke M G J

“…Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data…”
Get full text

Should we prefer biologics over nonbiological agents in psoriasis? by Thomas, Sarah E, van den Reek, Juul M P A

Get full text

Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis by Thomas, Sarah E., Barenbrug, Liana, Hannink, Gerjon, Seyger, Marieke M. B., de Jong, Elke M. G. J., van den Reek, Juul M. P. A.

“…Background and Objective The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival…”
Get full text

Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls by van den Reek, Juul M.P.A., Kievit, Wietske, Gniadecki, Robert, Goeman, Jelle J., Zweegers, Jeffrey, van de Kerkhof, Peter C.M., Seyger, Marieke M.B., de Jong, Elke M.G.J.

Get full text

Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients by Rodriguez-Rosales, Yessica A., Langereis, Jeroen D., Gorris, Mark A.J., van den Reek, Juul M.P.A., Fasse, Esther, Netea, Mihai G., de Vries, I. Jolanda M., Gomez-Muñoz, Laia, van Cranenbroek, Bram, Körber, Andreas, Sondermann, Wiebke, Joosten, Irma, de Jong, Elke M.G.J., Koenen, Hans J.P.M.

“…Neutrophil accumulation in the skin is a hallmark of psoriasis. Novel insights on neutrophil phenotypic and functional heterogeneity raise the question to what…”
Get full text

How to define a ‘super-responder’ to biologics in psoriasis studies by Thomas, Sarah E, van den Reek, Juul M P A, Seyger, Marieke M B, de Jong, Elke M G J

“…Recently, there has been an increase of publications on super-responders to biologic therapy for psoriasis.In this study, we aimed to contribute to this…”
Get full text